Immunome, Inc. Earnings Per Share (Basic)
Immunome, Inc. (IMNM) reported Earnings Per Share (Basic) of -$0.65 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-11
- Immunome, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$0.65.
- Immunome, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.48.
- Immunome, Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$0.74.
- Immunome, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$0.65.
- Immunome, Inc. earnings per share, basic for fiscal 2025 was -$2.43.
- Immunome, Inc. earnings per share, basic for fiscal 2024 was -$5.00.
- Immunome, Inc. earnings per share, basic for fiscal 2023 was -$5.38.
- Immunome, Inc. earnings per share, basic for fiscal 2022 was -$3.09.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.65 10-Q · filed 2026-08-11 | -$1.12 10-Q · filed 2026-08-11 | -$1.84 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$2.49 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2026-03-31 | -$0.48 10-Q · filed 2026-05-12 | -$1.19 derived: net income ÷ weighted average shares · filed 2026-05-12 | -$1.84 derived: net income ÷ weighted average shares · filed 2026-05-12 | -$2.35 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2025-12-31 | -$0.74 derived: net income ÷ weighted average shares · filed 2026-03-03 | -$1.39 derived: net income ÷ weighted average shares · filed 2026-03-03 | -$1.90 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$2.43 10-K · filed 2026-03-03 |
| 2025-09-30 | -$0.65 10-Q · filed 2025-11-06 | -$1.15 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$1.68 10-Q · filed 2025-11-06 | -$2.81 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2025-06-30 | -$0.50 10-Q · filed 2026-08-11 | -$1.02 10-Q · filed 2026-08-11 | -$2.16 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$2.93 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2025-03-31 | -$0.52 10-Q · filed 2026-05-12 | -$1.71 derived: net income ÷ weighted average shares · filed 2026-05-12 | -$2.50 derived: net income ÷ weighted average shares · filed 2026-05-12 | -$3.13 derived: net income ÷ weighted average shares · filed 2026-05-12 |
| 2024-12-31 | -$1.28 derived: net income ÷ weighted average shares · filed 2026-03-03 | -$2.07 derived: net income ÷ weighted average shares · filed 2026-03-03 | -$2.68 derived: net income ÷ weighted average shares · filed 2026-03-03 | -$5.00 10-K · filed 2026-03-03 |
| 2024-09-30 | -$0.78 10-Q · filed 2025-11-06 | -$1.39 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$3.72 10-Q · filed 2025-11-06 | -$5.69 derived: net income ÷ weighted average shares · filed 2025-11-06 |
| 2024-06-30 | -$0.60 10-Q · filed 2025-08-06 | -$2.97 10-Q · filed 2025-08-06 | -$5.02 derived: net income ÷ weighted average shares · filed 2025-08-06 | -$6.31 derived: net income ÷ weighted average shares · filed 2025-08-06 |
| 2024-03-31 | -$2.51 10-Q · filed 2025-05-12 | -$4.71 derived: net income ÷ weighted average shares · filed 2025-05-12 | -$6.38 derived: net income ÷ weighted average shares · filed 2025-05-12 | -$7.82 derived: net income ÷ weighted average shares · filed 2025-05-12 |
| 2023-12-31 | -$2.16 derived: net income ÷ weighted average shares · filed 2025-03-19 | -$3.53 derived: net income ÷ weighted average shares · filed 2025-03-19 | -$4.58 derived: net income ÷ weighted average shares · filed 2025-03-19 | -$5.38 10-K · filed 2025-03-19 |
| 2023-09-30 | -$0.36 10-Q · filed 2024-11-13 | -$0.81 derived: net income ÷ weighted average shares · filed 2024-11-13 | -$1.16 10-Q · filed 2024-11-13 | -$1.80 derived: net income ÷ weighted average shares · filed 2024-11-13 |
| 2023-06-30 | -$0.46 10-Q · filed 2024-08-12 | -$0.81 10-Q · filed 2024-08-12 | -$1.45 derived: net income ÷ weighted average shares · filed 2024-08-12 | -$2.20 derived: net income ÷ weighted average shares · filed 2024-08-12 |
| 2023-03-31 | -$0.35 10-Q · filed 2024-05-14 | -$0.99 derived: net income ÷ weighted average shares · filed 2024-05-14 | -$1.75 derived: net income ÷ weighted average shares · filed 2024-05-14 | |
| 2022-12-31 | -$0.64 derived: net income ÷ weighted average shares · filed 2024-03-28 | -$1.40 derived: net income ÷ weighted average shares · filed 2024-03-28 | -$3.09 10-K · filed 2024-03-28 | |
| 2022-09-30 | -$0.75 10-Q · filed 2023-11-09 | -$2.45 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | -$0.74 10-Q · filed 2023-08-09 | -$1.70 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | -$0.96 10-Q · filed 2023-05-05 | |||
| 2021-12-31 | -$0.65 derived: net income ÷ weighted average shares · filed 2023-03-16 | -$1.30 derived: net income ÷ weighted average shares · filed 2023-03-16 | -$2.14 10-K · filed 2023-03-16 | |
| 2021-09-30 | -$0.65 10-Q · filed 2022-11-14 | -$1.49 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | -$0.46 10-Q · filed 2022-08-05 | -$0.83 10-Q · filed 2022-08-05 | ||
| 2021-03-31 | -$0.37 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | -$5.26 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |